Analyst Summary: Cumberland Pharmaceuticals reported strong financial results for full year 2022, including an increase in cash flow from operations of $8 million and total cash of $20 million. The company also announced its move to a new headquarters in Nashville, Tennessee, and its plans to expand its organization to over 100 individuals. Cumberland continues to expand its portfolio of FDA-approved brands, including its newly formed sales division, Cumberland Oncology. The company also entered into international partnerships to introduce its products to new markets, including Vibativ in Puerto Rico, Vibativ in the Middle East, and Vibativ in South Korea. Additionally, Cumberland restructured its agreement with Nordic Pharma for the U.S. rights associated with the RediTrex brand. The company's net revenues increased to $42.9 million, a 15% increase over the prior-year period, and it reported a net income of $13.7 million, or $0.38 per share, for the year. The company's management provided forward-looking statements, expressing confidence in Cumberland's future growth and expansion efforts.